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Introduction
Golimumab is a fully human monoclonal antibody tar-
geting tumor necrosis factor-alpha (TNF-a), which plays
an important role in the pathogenesis of juvenile idio-
pathic arthritis. Golimumab was approved for the treat-
ment of rheumatoid arthritis, psoriatic arthritis and
ankylosing spondylitis.
Objectives
To assess the effectivity and safety of Gololimumab in
juvenile idiopathic arthritis.
Methods
We analysed retrospectively the data of all our patients
who have been treated with Golimumab (Simponi®)
every 28 days sub cutaneously.
Results
18 patients with the diagnosis of juvenile idiopathic arthri-
tis (15 with juvenile enthesitis associated arthritis, 2 with
juvenile psoriatic arthritis and 1 with juvenile idiopathic
polyarticular arthritis), for a mean time of 13.7 months per
patient (4-26 months). 16 patients have been treated with
other biologic agents before. In 13 patients Golimumab
was started because of disease progression, in 3 because of
intolerance to other biologic agents and in 2 because they
described severe phobia of injections.Mean number of
painful, swollen and limited joints were before and at the
end of the treatment period after 13.7 months (4.5/2.39;
1.78/0.94; 2.72/2.83). The mean value at baseline after
the mean follow up were of the physician global assess-
ment score (2.03/0.84), mean erythrocyte sedimentation
rate (8.72 mm/7.41 mm) and mean c-reactive protein
(4.36 mg/l/3.97 mg/l). 13 patients developed side effects,
one patient developed a severe adverse event (appendicitis
with consecutive appendectomy). None of the patients was
the drug discontinued because of the side effects.
Conclusion
According to this preliminary study in patients with JIA
golimumab seems to be a safe and effective treatment.
The data of the prospective study is pending.
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